Chardan Capital Maintains Buy on Editas Medicine, Raises Price Target to $4
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Chardan Capital analyst Geulah Livshits maintains Editas Medicine (NASDAQ:EDIT) with a Buy and raises the price target from $3.5 to $4.
Chardan Capital analyst Geulah Livshits maintains Editas Medicine (NASDAQ:EDIT) with a Buy and raises the price target from $3.5 to $4.